Chemomab Therapeutics (CMMB) Current Assets (2017 - 2025)

Chemomab Therapeutics' Current Assets history runs 9 years deep, the most recent figure standing at $13.4 million for Q4 2025.

• Quarterly Current Assets fell 16.3% year-over-year to $13.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.4 million (down 16.3% YoY) and the FY2025 annual result came in at $13.4 million, down 16.3% from the prior year.
• Current Assets was $13.4 million for Q4 2025 at Chemomab Therapeutics, up from $11.9 million in the prior quarter.
• Across five years, Current Assets topped out at $68.8 million in Q2 2021 and bottomed at $10.6 million in Q2 2025.
• A 5-year average of $34.0 million and a median of $25.0 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2021 — Current Assets jumped 791.2% — and 2023, when it plunged 54.1%.
• Chemomab Therapeutics' Current Assets stood at $62.7 million in 2021, then slumped by 33.42% to $41.7 million in 2022, then slumped by 49.93% to $20.9 million in 2023, then fell by 23.24% to $16.0 million in 2024, then slipped by 16.3% to $13.4 million in 2025.
• Business Quant data shows CMMB's Current Assets at $13.4 million in Q4 2025, $11.9 million in Q3 2025, and $10.6 million in Q2 2025.